BB Biotech reported a Q2 net loss of CHF?100m, primarily due to a ~10% depreciation in the USD/CHF exchange rate. Despite this, NAV rose 5.5% in USD, outperforming the Nasdaq Biotech Index by 1.5pp. The share price rose 10.5% in USD terms. From the beginning of 2025 to 1 August, the NAV discount narrowed from 15.0% to 10.9%.
LÄS MER
